BioPharmSignal logoBioPharmSignal

Biotech News

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fennec Pharmaceuticals Inc. (FENC)Fennec Pharmaceuticals Inc.Company update

RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant

Related news

FENCFennec Pharmaceuticals Inc.2026-08-05 11:01 EST

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

FENCFennec Pharmaceuticals Inc.2026-06-10 20:30 EST

Fennec Announces Results of Annual Meeting

ZNTLZentalis2026-06-01 21:00 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURAKura Oncology2026-08-07 11:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDYAIDEAYA Biosciences2026-07-31 10:00 EST

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-07-22 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FATEFate Therapeutics2026-08-03 20:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-07-14 20:26 EST

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

MGNXMacroGenics2026-07-02 13:25 EST

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

View all latest news

Fennec Pharmaceuticals Inc.

Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy. Pediatric Commercial Foundation PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through...

Recent company news

FENCFennec Pharmaceuticals Inc.2026-08-05 11:01 EST

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

FENCFennec Pharmaceuticals Inc.2026-06-15 10:00 EST

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

FENCFennec Pharmaceuticals Inc.2026-06-10 20:30 EST

Fennec Announces Results of Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-05-21 22:01 EST

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-05-18 20:30 EST

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
10.84 USD
Market cap
346.68M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States